> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pfizer Seeks U.S. Authorization for COVID-19 Vaccine in 28 Million Children Ages 5 to 11
- URL: https://www.theamericanquorum.com/taq-historical-2021-10-09-healthcare/
- Published: 2021-10-10T03:59:00.000Z
- Updated: 2021-10-10T03:59:00.000Z
- Description: Pfizer and BioNTech asked the FDA to authorize a lower-dose COVID-19 vaccine for children ages 5 to 11, opening a regulatory review that could make about 28 million U.S. children eligible for vaccination.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, #Import 2026-08-31 04:52

Pfizer and BioNTech have asked the Food and Drug Administration to authorize their COVID-19 vaccine for children ages 5 to 11, beginning a federal review that could make roughly 28 million additional U.S. children eligible for vaccination while schools continue to contend with the Delta variant.

The companies formally requested an amendment to the vaccine's emergency use authorization on Thursday after submitting initial pediatric trial data in late September. The proposed regimen uses two 10-microgram doses administered 21 days apart — one-third of the dose given to people 12 and older. Pfizer and BioNTech said in their [September trial report](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results?ref=theamericanquorum.com) that the lower dose produced neutralizing-antibody responses comparable to those observed in people ages 16 to 25 and had a favorable safety profile in the study.

## A new regulatory decision for a younger population

The pediatric application differs from the earlier authorization of the vaccine for adolescents because younger children have lower rates of severe COVID-19 than adults and because regulators must weigh the benefits of vaccination against uncommon adverse events with particular care. Pfizer's Phase 2/3 study enrolled 2,268 children ages 5 to 11\. The companies initially sent those data to the FDA on September 28, according to their [submission notice](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-initial-data-us-fda-pivotal?ref=theamericanquorum.com), and said a formal request for emergency authorization would follow.

The FDA has already scheduled a public meeting of its Vaccines and Related Biological Products Advisory Committee for October 26\. The agency's [meeting announcement](https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-october-26-2021-meeting-announcement?ref=theamericanquorum.com) says independent experts will discuss Pfizer-BioNTech's request to amend the existing emergency authorization for children 5 through 11\. The committee's recommendation will not bind the agency, but the FDA generally seeks its advice for major vaccine decisions.

Even if the FDA authorizes the pediatric formulation, vaccinations will not begin immediately. The Centers for Disease Control and Prevention and its Advisory Committee on Immunization Practices must then decide how the vaccine should be recommended for use in children. That two-step process mirrors the regulatory path used for adolescents and adults.

## Delta has changed the risk calculation for children

Children remain substantially less likely than older adults to develop severe COVID-19, but the Delta wave has demonstrated that pediatric illness is not negligible. A CDC [hospitalization study](https://www.cdc.gov/mmwr/volumes/70/wr/mm7036e2.htm?ref=theamericanquorum.com) published in September found that COVID-19-associated hospitalization rates among children and adolescents increased rapidly from late June through mid-August, coinciding with Delta becoming predominant in the United States.

The same report found hospitalization rates substantially higher among unvaccinated adolescents than among those who were fully vaccinated, although children under 12 were not yet eligible for any COVID-19 vaccine. Federal health officials have also emphasized that some hospitalized children have underlying conditions while others do not, making it difficult to identify a subgroup that carries all of the pediatric risk.

The FDA announced on October 1 that it would hold advisory meetings both on booster doses and on vaccines for younger children. In that [announcement](https://www.fda.gov/news-events/press-announcements/fda-hold-advisory-committee-meetings-discuss-emergency-use-authorization-booster-doses-and-covid-19?ref=theamericanquorum.com), Acting Commissioner Janet Woodcock said the agency understood the urgency parents felt about making vaccines available to younger children but would conduct a thorough review of safety and effectiveness data.

## The dose is smaller, but the safety questions are significant

Pfizer chose the 10-microgram dose after earlier-stage testing compared immune responses and tolerability at different dose levels. The company says the pediatric regimen generated antibody concentrations similar to those seen in young adults receiving the 30-microgram dose. The pivotal study was designed primarily to compare immune responses rather than to measure protection against severe disease, which is uncommon in this age group.

Regulators are expected to examine myocarditis closely. Rare cases of inflammation of the heart muscle or surrounding tissue have occurred most often in adolescent and young adult males after the second dose of mRNA vaccines. The pediatric trial is too small to identify an adverse event that occurs only once in tens of thousands of doses, so the FDA will have to model potential risk using data from older age groups while considering the lower pediatric dose.

That balance is one reason the agency has chosen a public advisory process. The October 26 meeting will allow outside experts to review Pfizer's data, FDA analyses and public comments before voting on whether the known and potential benefits outweigh the known and potential risks for children 5 to 11.

## Authorization could change schools and family life

If authorized and recommended, the vaccine would reach a population that has spent the current school year relying primarily on masks, ventilation, testing, quarantine and community vaccination to reduce risk. The Washington Post reported that about [28 million children](https://www.washingtonpost.com/health/2021/10/07/pfizer-biontech-childrens-vaccine-fda/?ref=theamericanquorum.com) fall within the 5-to-11 age range, making the decision one of the largest remaining expansions of U.S. vaccine eligibility.

The American Academy of Pediatrics has continued to report large numbers of pediatric infections during the Delta surge, while emphasizing that severe outcomes remain uncommon relative to the number of cases. That combination makes the policy question unusually sensitive: vaccination could prevent illness, missed school and some hospitalizations, but the acceptable threshold for vaccine risk is necessarily low in a population where most infections are not severe.

Pfizer's request does not settle that question. It starts the process by placing the company's clinical data before federal regulators and outside experts. The FDA will now evaluate the evidence, the advisory committee will debate it publicly, and the CDC will decide how any authorization should be translated into recommendations for families and clinicians.

For parents of elementary-school children, the timetable is becoming clearer. The federal government is no longer waiting for pediatric trial data; it is now deciding whether those data are sufficient to extend vaccination to the youngest large group of Americans still ineligible for a COVID-19 shot.